HIK

Hikma appoints Patrick Genestin to lead Generics Business Development

Retrieved on: 
Wednesday, June 9, 2021
Pharmaceutical companies, Hikma Pharmaceuticals, Health care, HIK, Health, Hikma, Pharmaceutical industry in China, Samih Darwazah

LONDON, June 9, 2021 /PRNewswire/ --Hikma Pharmaceuticals PLC(Hikma),the multinational pharmaceutical company, announces that Patrick Genestin has been appointed Vice President, Business Development, Generics.

Key Points: 
  • LONDON, June 9, 2021 /PRNewswire/ --Hikma Pharmaceuticals PLC(Hikma),the multinational pharmaceutical company, announces that Patrick Genestin has been appointed Vice President, Business Development, Generics.
  • Mr. Genestin brings to Hikma more than 25 years of experience in the pharmaceutical industry as a results-driven executive with strong financial, business development and M&A experience.
  • "Patrick is an established business development leader whose extensive industry experience will be critical to Hikma as we build on our successful track record," said Brian Hoffmann, President, Hikma Generics.
  • "I am excited to be joining Hikma at an important time for the company and the Generics business," said Mr. Genestin.

Hikma Pledges additional $40,000 to local US food banks and pantries in fight against hunger

Retrieved on: 
Thursday, March 18, 2021
Hikma, HIK, Food bank, Feeding America, Pantry, Companies of the United Kingdom, Companies, Industry economics)

LONDON, March 18, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it will grant an additional $40,000 USD to local food banks and pantries in the US communities in which it operates.

Key Points: 
  • LONDON, March 18, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it will grant an additional $40,000 USD to local food banks and pantries in the US communities in which it operates.
  • To date, the company has provided over 600,000 meals through its employee matching donation campaign raising more than $160,000 USD in its support of local food banks and pantries.
  • "Hikma is dedicated to serving our communities as so many people continue to struggle financially due to the COVID-19 pandemic," said Hana Ramadan, Vice President, Corporate Social Responsibility at Hikma.
  • Grove City, Ohio: Mid-Ohio Food Collective , an affiliate food bank of Feeding America, provides enough food for about 170,000 meals each day to help stabilize families.

Hikma receives favourable court ruling for its generic Vascepa®

Retrieved on: 
Thursday, September 3, 2020
Health, Articles, Hikma Pharmaceuticals, Hikma, HIK, Health technology, Pharmaceutical industry in China, Pharmaceutical industry, Amarin Corporation

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.

Key Points: 
  • Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.
  • For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.
  • We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.
  • For more information, please visit: www.hikma.com
    View original content to download multimedia: http://www.prnewswire.com/news-releases/hikma-receives-favourable-court-...
    SOURCE Hikma Pharmaceuticals USA Inc.

Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership

Retrieved on: 
Wednesday, August 26, 2020
Hikma Pharmaceuticals, Hikma, Health, Cerner, HIK, Italian Academy of Orthodontic Technology, Heal, Subscription, Companies

LONDON, Aug. 26, 2020 /PRNewswire/ --Hikma Pharmaceuticals PLC (Hikma) announces that its venture capital arm, Hikma Ventures has participated in a CAD4.0 million Series A round of financing for SeamlessMD .

Key Points: 
  • LONDON, Aug. 26, 2020 /PRNewswire/ --Hikma Pharmaceuticals PLC (Hikma) announces that its venture capital arm, Hikma Ventures has participated in a CAD4.0 million Series A round of financing for SeamlessMD .
  • The round was led by MEDTEQ, bringing the company's total funding to CAD7.4 million.
  • Anges Qubec, AIoT Health, and health IT entrepreneur Sanjay Malaviya also participated in the oversubscribed round.
  • SeamlessMD's financing follows a period of establishing category leadership, having become the first digital patient engagement platform to hold validated, turn-key integrations with leading electronic health record companies Epic and Cerner.

Hikma launches employee matching donation campaign to support local US food banks and pantries

Retrieved on: 
Monday, May 11, 2020
Food bank, Hikma, HIK

EATONTOWN, N.J., May 11, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, announces the launch of an employee matching donation campaign to support local food banks and pantries in the US communities in which Hikma operates.

Key Points: 
  • EATONTOWN, N.J., May 11, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, announces the launch of an employee matching donation campaign to support local food banks and pantries in the US communities in which Hikma operates.
  • Hoffmann continued, "We are proud to launch this campaign, which will support our local food banks and pantries as they face the challenges of meeting the sudden rise in local community members seeking support.
  • The employee matching donation campaign builds on Hikma's existing relationships with the following food banks and pantries in each of its local markets:
    Bedford, OH: The Emergency Assistance Center (TEAC) has provided food, clothing and personal hygiene items to Northern Summit County neighbors in need for more than 25 years.
  • Every dollar raised will go directly to each organizations' COVID-19 relief efforts and will be used to support local families in need.

Altoida Inc. Secures Investment from Hikma Ventures to Drive Better Clinical Outcomes for Brain Diseases

Retrieved on: 
Monday, May 4, 2020
Branches of biology, Biomarkers, Biology, Life sciences, Cell biology, Hikma, HIK, Corporate venture capital

Hikma Ventures is the perfect addition to our investor syndicate and an important partner as we continue to execute on our clearly defined commercialization strategy."

Key Points: 
  • Hikma Ventures is the perfect addition to our investor syndicate and an important partner as we continue to execute on our clearly defined commercialization strategy."
  • Altoida leverages predictive digital biomarkers to drive better clinical outcomes for brain disease.
  • "We are excited to invest in Altoida and their digital health technology, which is helping patients and healthcare providers by reinventing digital biomarkers to drive better clinical outcomes for brain disease," said Lana Ghanem, Managing Director of Hikma Ventures.
  • Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.

Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Retrieved on: 
Thursday, January 9, 2020
Hikma, HIK, Food and Drug Administration, Health, Articles

Hikma will seek approval for the product under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway, with filing expected in 2021.

Key Points: 
  • Hikma will seek approval for the product under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway, with filing expected in 2021.
  • "We are proud to be working with Hikma," said Sarah Howell, Chief Executive Officer of Arecor.
  • We look forward to the joint development of this first product as part of a broad collaboration with Hikma."
  • Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.

Hikma Ventures leads Series A financing for development of Winterlight Labs' AI vocal technology to detect central nervous system disorders and track efficacy of treatments

Retrieved on: 
Monday, November 18, 2019
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Aging-associated diseases, Hikma, Psychiatry, Dementia, HIK, Health, Cognition

Lana Ghanem, Managing Director of Hikma Ventures, said, "We are very excited to enter into the field of vocal diagnostics by leading the investment in Winterlight Labs.

Key Points: 
  • Lana Ghanem, Managing Director of Hikma Ventures, said, "We are very excited to enter into the field of vocal diagnostics by leading the investment in Winterlight Labs.
  • "The technology our team is creating will reshape the way healthcare systems track, screen for and assess the effectiveness of treatments for various central nervous system diseases."
  • Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.
  • By analysing speech alone, the technology can detect cognitive impairment associated with dementia and mental illness as track the efficacy of related treatments.

Prophet Takes Home Five Wins at the U.S. Transform Awards

Retrieved on: 
Friday, November 8, 2019
HIK, Hikma, Transform

In March 2019, Prophet was awarded the Grand Prix - the highest accolade at Transform Awards Europe 2019 - for the rebranding of Hikma , a multinational pharmaceutical company.

Key Points: 
  • In March 2019, Prophet was awarded the Grand Prix - the highest accolade at Transform Awards Europe 2019 - for the rebranding of Hikma , a multinational pharmaceutical company.
  • A few months later, Prophet took home eight awards at the Transform Awards MENA.
  • We are honored to have work recognized by the Transform organization in the new North American awards, as well as our work in Europe and Asia-Pacific.
  • Prophets distinctions at the U.S. Transform Awards stand as testaments to the teams human-centric and creative approach to helping its clients to find better ways to achieve uncommon growth.

Hikma Ventures participates in $11 million funding round for Pillo Health

Retrieved on: 
Thursday, May 30, 2019
Hikma, HIK, Venture capital, Corporate venture capital

LONDON, May 30,2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) today announced its venture capital arm Hikma Ventures has participated in an $11 million financing round forBoston-based Pillo Health.

Key Points: 
  • LONDON, May 30,2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) today announced its venture capital arm Hikma Ventures has participated in an $11 million financing round forBoston-based Pillo Health.
  • "Our investment in Pillo Health underscores our deep commitment to developing innovative healthcare technology solutions that will put better health within reach for more patients around the world," saidLana Ghanem, Managing Director Hikma Ventures.
  • Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.
  • Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma.